As gene therapy moves beyond rare diseases, the gene therapy field faces a common challenge: how to scale AAV manufacturing efficiently. Transient transfection methods while effective at lower scales, often fall short when higher doses and larger patient populations are involved slowing down clinical progress and increasing costs.
In this webinar, we’ll explore how stable AAV producer cell lines can help address these limitations by offering a cost-effective and scalable approach to AAV production.
Michael Mühle
Michael.muhle@cytiva.com
Head of Viral Vector Production Science, Cytiva
Dr. Michael Mühle is a Biotechnology engineer by training and concluded his studies with an internship at the University of California and a Diploma-Thesis at the Max Delbrück Center for Molecular Medicine in 2009. He obtained further scientific experience by working in the HIV-1 vaccine development field and identification of HIV-mediated immunosuppression mechanisms during his PhD and Postdoc phase at the Robert Koch-Institute before transitioning to the industrial field in 2015. As part of his Bioprocess Engineer and Scientist role, Michael was responsible in setting up a 1000 L mAb GMP facility and supervising viral vector downstream development projects at the Berlin-based CDMO ProBioGen. In 2021, he took over the team lead for the newly formed viral vector upstream and downstream development and GMP production group in the same company. Since 3 years, he is now heading the viral vector production group at the Cologne site of Cytiva formerly known as CEVEC Pharmaceuticals and supervises characterization, process development and scale-up activities of customer and internal AAV cell line development projects.